Answers are grounded in this paper and cite their sources.
ABSTRACT 68Ga faces a renaissance initiated by the development of new 68Ge/68Ga radionuclide generators, sophisticated 68Ga radiopharmaceuticals, preclinical research and state-of-the-art clincial diagnoses via positron emission tomography/computed tomography (PET/CT). A new type of 68Ge/68Ga generator became commercially available in the first years of the 21st century, with eluates based on hydrochloric acid. These generators provided ‘cationic’ 68Ga instead of ‘inert’ 68Gacomplexes, and opened new pathways of MeIII radiopharmaceutical chemistry. The last decade has seen a 68Ga rush. Increasing interest in generator-based 68Ga radiopharmaceuticals in diagnostic applications has been accompanied by its potential use in the context of diease treatment planning, made possible by the inherent option expressed by theranostics. However, widespread acceptance and clinical application requires optimization of 68Ge/68Ga generators both from chemical and regulatory perspectives. How to cite this article Rösch F. 68Ge/68Ga Generators and 68Ga Radiopharmaceutical Chemistry on Their Way into a New Century. J Postgrad Med Edu Res 2013;47(1):18-25.
No takes yet. Share an insight, caveat, or question.
Frank Rösch (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: